Starpharma signs DEP® ADC Research Agreement with MSD

Rhea-AI Summary

On February 11, 2021, Starpharma (OTCQX: SPHRY) announced a Research Agreement with MSD to evaluate dendrimer-based Antibody Drug Conjugates (ADCs) using their proprietary DEP^® technology. This collaboration aims to enhance ADC characteristics, building on Starpharma's successful preclinical studies, including their DEP^® HER-2 ADC, which demonstrated significant tumor regression and 100% survival in models. Starpharma already has four clinical-stage oncology products developed from the DEP^® technology, one of which is in partnership with AstraZeneca.

Positive

• Research Agreement with MSD enhances Starpharma's ADC development potential.
• Future studies will leverage DEP^® technology's advantages over conventional ADCs.
• Previous preclinical studies showed promising results, including 100% survival rates.

Negative

• None.

MELBOURNE, Australia, Feb. 11, 2021 /PRNewswire/ -- Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma's proprietary DEP^® technology.

Dr Jackie Fairley, CEO of Starpharma commented: "MSD is a recognised leader in oncology, and we are delighted to have signed this new Research Agreement in such an innovative and valuable area."

DEP^® ADCs exploit the unique potential of Starpharma's DEP^® technology to provide enhanced characteristics to ADCs including greater homogeneity, site specific attachment, and higher drug antibody ratio (DAR), than conventional ADC approaches. DEP^® ADCs are the subject of internal and partnered programs.

Starpharma has previously demonstrated the significant advantages conveyed by DEP^® ADCs in multiple preclinical studies, including its DEP^® HER-2 ADC, which showed significant tumour regression and 100% survival, outperforming Herceptin & Kadcyla in a human ovarian cancer model. Starpharma's DEP^® technology has already yielded four clinical stage oncology products, including one under development by AstraZeneca.

Media: Sumit Media Grant Titmus Mob: +61 419 388 161 grant@sumitmedia.com.au

Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer Nigel Baade, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com  4-6 Southampton Crescent Abbotsford Vic 3067

Disclosure This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

 

View original content:http://www.prnewswire.com/news-releases/starpharma-signs-dep-adc-research-agreement-with-msd-301227420.html

SOURCE Starpharma

FAQ

What is the recent agreement between Starpharma and MSD about?

Starpharma signed a Research Agreement with MSD for preclinical research on dendrimer-based Antibody Drug Conjugates using Starpharma's DEP^® technology.

What are the benefits of Starpharma's DEP^® technology?

DEP^® technology enhances ADC characteristics such as higher drug antibody ratio, greater homogeneity, and site-specific attachment.

What results did Starpharma's DEP^® HER-2 ADC achieve?

The DEP^® HER-2 ADC showed significant tumor regression and a 100% survival rate in human ovarian cancer models.

How many clinical-stage oncology products does Starpharma have?

Starpharma has developed four clinical-stage oncology products from its DEP^® technology.